Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma

Cytokine

Volumn 54, Issue 1, 2011, Pages 100-107

  Tsubaki, Masanobu ^a   Yamazoe, Yuzuru ^a,b   Yanae, Masashi ^a,c   Satou, Takao ^c   Itoh, Tatsuki ^c   Kaneko, Junichi ^a   Kidera, Yasuhiro ^a,b   Moriyama, Kenzo ^b   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINDAI UNIVERSITY HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Angiogenic factor; ERK; Ras; Statin

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RAS PROTEIN; SCATTER FACTOR; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PRENYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTE GROWTH FACTOR; MEVALONIC ACID; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POLYISOPRENYL PHOSPHATES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952071312     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.01.005     Document Type: Article

References (31)

1. Himelstein B.P. Osteosarcoma and other bone cancers. Curr Opin Oncol 1998, 10:326-333.
2. Bruland O.S., Høifødt H., Saeter G., Smeland S., Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005, 11:4666-4673.
3. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
4. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
5. Waxman D.J., Schwartz P.S. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003, 63:8563-8572.
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
7. Quan G.M., Choong P.F. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 2006, 25:707-713.
8. Arihiro K., Inai K. Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma. Pathol Int 2001, 51:100-106.
9. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
10. Wu J., Wong W.W., Khosravi F., Minden M.D., Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004, 64:6461-6468.
11. Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y., et al. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol Cell Biochem 2005, 269:109-114.
12. Graaf M.R., Richel D.J., van Noorden C.J., Guchelaar H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004, 30:609-641.
13. Sonnemann J., Eckervogt V., Truckenbrod B., Boos J., Winkelmann W., van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs 2003, 14:767-771.
14. Kim J.S., Pirnia F., Choi Y.H., Nguyen P.M., Knepper B., Tsokos M., et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 2000, 19:6082-6090.
15. Fromigué O., Ha E., Modrowski D., Bouvet S., Jacquel A., Auberger P., et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 2006, 13:1845-1856.
16. Asakage M., Tsuno N.H., Kitayama J., Kawai K., Okaji Y., Yazawa K., et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs. 2004, 15:625-632.
17. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T., et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001, 495:159-166.
18. Feng C., Han A., Ye C., Xu R., Li M. The HMG-CoA reductase pathway, statins and angioprevention. Semin Ophthalmol 2006, 21:29-35.
19. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Asano T., Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004, 10:8648-8655.
20. Sondergaard T.E., Pedersen P.T., Andersen T.L., Søe K., Lund T., Ostergaard B., et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 2009, 27:17-22.
21. Konstantinopoulos P.A., Papavassiliou A.G. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci 2007, 28:6-13.
22. Chang E.J., Kim H.H., Huh J.E., Kim I.A., Seung Ko J., Chung C.P., et al. Low proliferation and high apoptosis of osteoblastic cells on hydrophobic surface are associated with defective Ras signaling. Exp Cell Res 2005, 303:197-206.
23. Miyoshi K., Wakioka T., Nishinakamura H., Kamio M., Yang L., Inoue M., et al. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization. Oncogene 2004, 23(33):5567-5576.
24. Tsubaki M., Kato C., Nishinobo M., Ogaki M., Satou T., Ito T., et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Cancer Sci 2008, 99:152-158.
25. Morgan M.A., Sebil T., Aydilek E., Peest D., Ganser A., Reuter C.W. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 2005, 130:912-925.
26. Park I.H., Kim J.Y., Jung J.I., Han J.Y. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010, 28:791-799.
27. Hatton J.P., Pooran M., Li C.F., Luzzio C., Hughes-Fulford M. A short pulse of mechanical force induces gene expression and growth in MC3T3-E1 osteoblasts via an ERK 1/2 pathway. J Bone Miner Res 2003, 18:58-66.
28. Zeng Z.Z., Yellaturu C.R., Neeli I., Rao G.N. 5(S)-hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2. J Biol Chem 2002, 277:41213-41219.
29. Chattopadhyay N., MacLeod R.J., Tfelt-Hansen J., Brown E.M. 1alpha, 25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab 2003, 284:E219-E227.
30. Wu D., Peng F., Zhang B., Ingram A.J., Kelly D.J., Gilbert R.E., et al. PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol 2009, 20:554-566.
31. Lehmann K., Janda E., Pierreux C.E., Rytömaa M., Schulze A., McMahon M., et al. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000, 14:2610-2622.